Homologous recombination deficiency testing in ovarian cancer: the diagnostic experience of a referral Italian institution
Recently, precision medicine has drastically modified clinical paradigm for the clinical stratification of high-grade serous ovarian cancer (HGSOC) patients. International societies approved poly (ADP-ribose) polymerase (PARP) inhibitors (PARPIs) to treat platinum-sensitive From May 2023 to Jan 2024 molecular records from 147 HGSOC patients simultaneously tested for Overall, 2 out of 147 (1.3%) cases were morphologically classified as inadequate. Simultaneous HRD testing is a reliable method for the clinical management of HGSOC patients.